Skip to main content

Akeega FDA Approval History

Last updated by Judith Stewart, BPharm on Aug 15, 2023.

FDA Approved: Yes (First approved August 11, 2023)
Brand name: Akeega
Generic name: abiraterone acetate and niraparib
Dosage form: Tablets
Company: Johnson & Johnson Innovative Medicine
Treatment for: Prostate Cancer

Akeega (abiraterone acetate and niraparib) is a CYP17 inhibitor and a poly (ADP-ribose) polymerase (PARP) inhibitor combination indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).

Development timeline for Akeega

DateArticle
Aug 11, 2023Approval FDA Approves Akeega (niraparib and abiraterone acetate) for the Treatment of Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.